# A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06239155/  
OnCo record `nct06239155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AST-3424 in hepatocellular carcinoma, run by Ascentawits Pharmaceuticals, Ltd, active and no longer recruiting.

## Summary

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239155 by Ascentawits Pharmaceuticals, Ltd, with 51 participants enrolled, started 2019-09-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: AST-3424.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06239155
- Phase: 1/2
- Setting: Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of AST-3424 in Treatment of Patients With Advanced Solid Tumors and Its Correlation With AKR1C3 Enzyme Expression
- Sponsor: Ascentawits Pharmaceuticals, Ltd
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT06239155: https://clinicaltrials.gov/study/NCT06239155

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06239155.json